Time to discuss PREFER results!

We are getting close to issuing recommendations for when and how patient preferences can support decision-making for industry, regulators, health technology assessors and payers. Our clinical case studies are delivering results. And we have developed a framework for patient input to decision making that is currently under evaluation by EMA and EUnetHTA and are looking forward to a public consultation process later this summer. In the meantime, we invite everyone who is interested in patient preferences and the PREFER approach to discuss our work in a series of webinars this year, and the upcoming DIA workshop in June. 

Medical products are developed by pharma companies, approved by regulators, and assessed by health technology assessment bodies. But in the end, the medicines and medical products are meant for patients. All agree that the patient perspective is important, but there hasn't been consensus on the best way to include it. We are developing recommendations for when and how to best give patients a voice in medicine development using a structured preference approach. The recommendations will build on the results and experience from the whole project, and now it is high time to invite patients, regulators, HTA bodies and payers, the pharma industry and the patient preference research community to discuss our results! 

On 26 April, we organised a webinar on the value of patient preferences. This was the first in a series of webinars presenting and discussing results from the project that will be spread out accross 2021. So far, we have dates for two: a webinar on patient involvement in patient preference studies on 11 June and one webinar on the PREFER research agenda on 1 July. These and all future PREFER events are advertised in our calendar

We also invite you to a DIA/PREFER workshop on patient preferences on 15-16 June. The workshop has been funded by PREFER partners, and you can register free of charge. We hope that the workshop and webinars together will spark an interest in our framework for patient input that is currently under evaluation by EMA and EUnetHTA. This means we are adding an external multi-stakeholder evaluation of the evidence we present through a scientific advice process, where the result will be an opinion, that will be shared in a public consultation that we hope can happen this summer. 

Want to know more about what is going on in PREFER? Follow us on Twitter, LinkedIn, YouTube or sign up to receive our newsletter

By Josepine Fernow





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).